文献速递乳腺癌支持与姑息治疗

两种随机双盲试验的汇总分析:比较拟议生物类似药LA-EP2006与参照培非格司亭在乳腺癌中的表现

Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
PubMed 文献 · Ann Oncol · 2017-01-01

该汇总分析纳入两项设计相似的多国前瞻性随机双盲III期研究,共624例接受TAC化疗的乳腺癌患者,比较LA-EP2006与参照培非格司亭。第一周期重度中性粒细胞减少平均持续时间两组相似(1.05±1.055天 vs 1.01±0.958天),治疗差异-0.04天(95%CI:-0.19至0.11),满足等效标准。安全性和耐受性相似,未报告中和抗体。

要点

  • LA-EP2006组与参照组第一周期重度中性粒细胞减少平均持续时间分别为1.05±1.055天和1.01±0.958天。
  • 治疗差异为-0.04天(95%CI:-0.19至0.11),95%CI在预设±1天等效界值内。
  • 绝对中性粒细胞计数最低值和发热性中性粒细胞减少发生率两组相似,未报告中和抗体。

核心结论

  • 该汇总分析作为整体证据方法的一部分,证实拟议生物类似药培非格司亭LA-EP2006在接受TAC化疗的乳腺癌患者中与参照培非格司亭具有可比的有效性和安全性。

研究设计与样本

  • 汇总两项独立、多国、前瞻性、随机、对照、双盲III期研究(PROTECT-1和PROTECT-2,NCT01735175;NCT01516736)的数据,两项研究设计相似。
  • 共624例接受骨髓毒性(新)辅助TAC(多西他赛、多柔比星和环磷酰胺)化疗且需要粒细胞集落刺激因子的乳腺癌患者被随机分配(LA-EP2006组n=314;参照组n=310)。

主要发现

  • 主要终点第一周期重度中性粒细胞减少平均持续时间在LA-EP2006组和参照组分别为1.05±1.055天和1.01±0.958天,治疗差异为-0.04天(95%CI:-0.19至0.11),满足等效标准(95%CI在预设±1天界值内)。
  • 次要终点如绝对中性粒细胞计数最低值和发热性中性粒细胞减少发生率在LA-EP2006组与参照培非格司亭组之间也相似。
  • LA-EP2006的安全性和耐受性特征与参照培非格司亭相似,未报告中和抗体。

关键数值与推荐

  • 等效标准为第一周期重度中性粒细胞减少平均持续时间治疗差异的95%CI在预设±1天界值内。
  • LA-EP2006组与参照组第一周期重度中性粒细胞减少平均持续时间分别为1.05±1.055天和1.01±0.958天,治疗差异-0.04天(95%CI:-0.19至0.11)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Following the functional and physicochemical characterization of a proposed biosimilar, comparative clinical studies help to confirm biosimilarity by demonstrating similar safety and efficacy to the reference product in a sensitive patient population. PATIENTS AND METHODS: LA-EP2006 is a proposed biosimilar that has been developed for pegfilgrastim, a long-acting form of granulocyte colony-stimulating factor for the prevention of neutropenia. The current analysis reports data pooled from two independent, multinational, prospective, randomized, controlled, double-blind phase III studies of similar design comparing the safety and efficacy of reference pegfilgrastim with LA-EP2006 in patients with breast cancer receiving myelotoxic (neo)adjuvant TAC (docetaxel, doxorubicin, and cyclophosphamide) chemotherapy and requiring granulocyte colony-stimulating factor. RESULTS: A total of 624 patients were randomized in the PROTECT-1 and PROTECT-2 studies (NCT01735175; NCT01516736) (LA-EP2006: n = 314; reference: n = 310). Baseline characteristics of patients were well balanced across treatment groups. The primary end point, mean duration of severe neutropenia in the first chemotherapy cycle was similar in both the LA-EP2006 and reference groups (1.05 ± 1.055 days versus 1.01 ± 0.958 days), with a treatment difference of - 0.04 days [95% confidence interval (CI): -0.19 to 0.11] that met the equivalence criteria (the 95% CI were within the defined margin of ±1 day). Secondary end points, such as the nadir of absolute neutrophil count and the incidence of febrile neutropenia, were also similar between LA-EP2006 and reference pegfilgrastim. The safety and tolerability profile of LA-EP2006 was similar to that observed with reference pegfilgrastim, and there were no reports of neutralizing antibodies. CONCLUSIONS: This pooled analysis confirms, as a part of totality of evidence approach, that the proposed biosimilar pegfilgrastim LA-EP2006 has a comparable efficacy and safety profile to reference pegfilgrastim in patients with breast cancer receiving TAC chemotherapy. CLINICAL TRIAL NUMBERS: NCT01735175 and NCT01516736.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Blackwell K, Gascon P, Jones CM, et al. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Ann Oncol. 2017. PMID: 28637287. doi:10.1093/annonc/mdx303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。